1-2406580-CAG-C
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_002617.4(PEX10):βc.814_815delβ(p.Leu272ValfsTer66) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000341 in 1,613,414 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Synonymous variant affecting the same amino acid position (i.e. L272L) has been classified as Likely benign.
Frequency
Consequence
NM_002617.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
PEX10 | NM_002617.4 | c.814_815del | p.Leu272ValfsTer66 | frameshift_variant | 5/6 | ENST00000447513.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
PEX10 | ENST00000447513.7 | c.814_815del | p.Leu272ValfsTer66 | frameshift_variant | 5/6 | 1 | NM_002617.4 | P4 |
Frequencies
GnomAD3 genomes AF: 0.0000591 AC: 9AN: 152186Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000360 AC: 9AN: 250340Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135662
GnomAD4 exome AF: 0.0000315 AC: 46AN: 1461110Hom.: 0 AF XY: 0.0000316 AC XY: 23AN XY: 726892
GnomAD4 genome AF: 0.0000591 AC: 9AN: 152304Hom.: 0 Cov.: 33 AF XY: 0.0000671 AC XY: 5AN XY: 74472
ClinVar
Submissions by phenotype
Peroxisome biogenesis disorder 6A (Zellweger) Pathogenic:4
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Aug 16, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | The PEX10 c.874_875delCT (p.Leu292ValfsTer66) variant causes a frameshift and is predicted to result in an elongation of the protein. The p.Leu292ValfsTer66 variant has been reported in at least four studies in which it is found in a homozygous state in at least 13 individuals with Zellweger syndrome and in an additional three alleles of unknown zygosity (Okumoto et al. 1998; Shimozawa et al. 2003; Krause et al. 2009; Ebberink et al. 2011). Eleven homozygotes for the p.Leu292ValfsTer66 variant shared a common haplotype, suggesting a founder effect for this variant in the Japanese population (Shimozawa et al. 2003). Control data are unavailable for the variant which is reported at a frequency of 0.00005 in the European (non-Finnish) population of the Exome Aggregation Consortium. The frameshift caused by the p.Leu292ValfsTer66 variant interrupts a RING motif that is essential for protein function (Okumoto et al. 1998). In vivo complementation analyses in patient fibroblasts demonstrated that the p.Leu292ValfsTer66 variant results in a deficiency in PEX10 protein activity (Okumoto et al. 1998). Based on the potential impact of frameshift variants and the supporting evidence, the p.Leu292ValfsTer66 variant is classified as pathogenic for Zellweger syndrome. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 01, 2003 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 17, 2024 | - - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 11, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 26, 2024 | Published functional studies demonstrated a loss of PEX10 activity in an in vitro assay, suggesting a damaging effect (PMID: 10862081); Frameshift variant predicted to result in protein elongation, as the last 55 amino acids are replaced with 65 different amino acids, and other loss-of-function variants have been reported downstream in HGMD; Also known as 814-815delCT; This variant is associated with the following publications: (PMID: 10862081, 19142205, 9700193, 12794690, 34234304) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Oct 09, 2017 | - - |
Peroxisome biogenesis disorder Pathogenic:1Other:1
not provided, no classification provided | literature only | GeneReviews | - | Common allele in the Japanese population, where it appears to have arisen once on an ancestral haplotype. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 30, 2016 | Variant summary: The PEX10 c.874_875delCT (p.Leu292Valfs) variant causes a frameshift and is predicted to result in an elongation of the protein. Okumoto_1998 reported the variant to result in a protein entirely lacking the RING motif located immediately downstream of the mutated site, and multiple functional studies show lack of PEX10 activity as a result of the variant. This variant was found in 6/118582 control chromosomes at a frequency of 0.0000506, which does not exceed the estimated maximal expected allele frequency of a pathogenic PEX10 variant (0.001118). The variant was reported in numerous affected individual, and was reported as a Japanese founder mutation. Taken together, this variant is classified as pathogenic. - |
Peroxisome biogenesis disorder 6B Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Aug 16, 2016 | - - |
Peroxisome biogenesis disorder 6A (Zellweger);C3553948:Peroxisome biogenesis disorder 6B Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 14, 2022 | - - |
Peroxisome biogenesis disorder, complementation group 7 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 28, 2024 | This sequence change creates a premature translational stop signal (p.Leu292Valfs*66) in the PEX10 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 55 amino acid(s) of the PEX10 protein. This variant is present in population databases (rs61752093, gnomAD 0.02%). This premature translational stop signal has been observed in individuals with Zellweger peroxisome deficiency syndrome (PMID: 9700193, 10862081, 12794690, 17041890, 19142205, 21031596). It is commonly reported in individuals of Japanese ancestry (PMID: 12794690). This variant is also known as c.814βΓΓ¬815delCT and Leu272fs. ClinVar contains an entry for this variant (Variation ID: 296273). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects PEX10 function (PMID: 9700193, 10862081). For these reasons, this variant has been classified as Pathogenic. - |
Zellweger spectrum disorders Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at